NanoViricides, Inc. Update: FluCide Drug Candidates Significantly Superior to Tamiflu in Animal Studies Against H3N2 and H1N1 Viruses - Company Announces That cGMP Facility Project has Entered Detailed Design Phase

Published: Jan 15, 2013

WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC) (the "Company") provides an update on its influenza program. The Company states that in a highly lethal animal model against an H3N2 Influenza virus strain, very similar to the current dominant influenza strain, the Company’s oral anti-influenza drug candidate has shown significantly superior efficacy to Tamiflu® (oseltamivir). This oral anti-influenza drug candidate and its related injectable drug variant have both shown significantly superior efficacy to Tamiflu against influenza A H1N1 strain in the same animal model. The H1N1 strain we used is of the same type as the 2009 epidemic influenza virus, although not the same strain. The Company has previously reported on these studies.

Back to news